- Home
- JANX vs RBCAA Comparison
JANX vs RBCAA Comparison
Compare JANX & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- RBCAA
- Stock Information
- Founded
- JANX 2017
- RBCAA 1974
- Country
- JANX United States
- RBCAA United States
- Employees
- JANX N/A
- RBCAA N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- RBCAA Major Banks
- Sector
- JANX Health Care
- RBCAA Finance
- Exchange
- JANX Nasdaq
- RBCAA Nasdaq
- Market Cap
- JANX 1.4B
- RBCAA 1.3B
- IPO Year
- JANX 2021
- RBCAA 1998
- Fundamental
- Price
- JANX $27.01
- RBCAA $68.66
- Analyst Decision
- JANX Strong Buy
- RBCAA Hold
- Analyst Count
- JANX 11
- RBCAA 1
- Target Price
- JANX $76.55
- RBCAA N/A
- AVG Volume (30 Days)
- JANX 927.5K
- RBCAA 25.3K
- Earning Date
- JANX 11-05-2025
- RBCAA 10-17-2025
- Dividend Yield
- JANX N/A
- RBCAA 2.62%
- EPS Growth
- JANX N/A
- RBCAA 24.34
- EPS
- JANX N/A
- RBCAA 6.44
- Revenue
- JANX $439,000.00
- RBCAA $378,269,000.00
- Revenue This Year
- JANX N/A
- RBCAA $15.62
- Revenue Next Year
- JANX $91.66
- RBCAA N/A
- P/E Ratio
- JANX N/A
- RBCAA $10.70
- Revenue Growth
- JANX N/A
- RBCAA 16.59
- 52 Week Low
- JANX $21.73
- RBCAA $56.79
- 52 Week High
- JANX $71.71
- RBCAA $80.68
- Technical
- Relative Strength Index (RSI)
- JANX 59.54
- RBCAA 40.32
- Support Level
- JANX $25.62
- RBCAA $68.17
- Resistance Level
- JANX $27.70
- RBCAA $72.47
- Average True Range (ATR)
- JANX 1.56
- RBCAA 1.68
- MACD
- JANX 0.30
- RBCAA -0.19
- Stochastic Oscillator
- JANX 69.68
- RBCAA 11.36
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.